

Atty. Docket 107 a TROS 187.0003-00000		Appln. No.	10/798,421	
Applicant	John DEVANE			
Filing Date	March 12, 2004	Group:	3 1014	

U.S. PATENT DOCUMENTS						
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	Filing Date If Appropriate
PS	Publication No. US 2001/0014678 A1	Published 08/16/2001	Cary	514	252.15	02/20/2001
Ps.	Publication No. US 2002/0004065 A1	Published 01/10/2002	Kanios	424	449	01/19/2001
PS	Publication No. US 2002/0016370 A1	Published 02/07/2002	Shytle, et al.	514	661	06/15/2001
PS	Publication No. US 2002/0016371 A1	Published 02/07/2002	Shytle, et al.	514	661	06/15/2001
P5	Publication No. US 2002/0103109 A1	Published 08/01/2002	Glick, et al.	514	1	01/18/2002
75	6,121,289	09/19/2000	Houdi	514	315	10/09/1998
PS	6,034,079	03/07/2000	Sanberg, et al.	514	225.8	11/23/1998

	Document Number	Publication Date	Country	Class	Sub Class	Translation Yes or No
19	WO 03/090731	11/6/2003	PCT	A61K	31/05	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)						
75'	Kachur, et al., "Pharmacological effects of 1,2,3,5,6,10b-hexahydropyrido[2,3g]indolizine, a bridged-nicotine analog," <i>Life Sci., 38</i> (4): 323-330 (1986).						
Ps'	Nordberg, et al., "Uptake and regional distribution of (+)-(R)- and (-)-(S)-N-[methyl-11C]-nicotine in the brains of Rhesus monkey. An attempt to study nicotinic receptors in vivo," J. Neural Transm. Park Dis. Dement. Sect., 1(3): 195-205 (1989).						
PS	Papke, et al., "Analysis of mecamylamine stereoisomers on human nicotinic receptor subtypes," J. Pharmacol. Exp. Ther., 297(2): 646-656 (2001).						
PS	Sloan, et al., "Nature of nicotine binding to rat brain P ₂ fraction," Pharmacol. Biochem. Behav., 20(6):899-909 (1984)						

Page 1 of 2

Phyllis Spirack 6/10/04

OMB No. 0651-0011



Atty. Docket No. 2345 0003-00000		Appin. No.	10/798,421	
Applicant	John DEVANE			
Filing Date	March 12, 2004	Group:	unassigned	

	OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
PS	Sloan, et al., "The comparative binding characteristics of nicotinic ligands and their pharmacol Pharmacol. Biochem. Behav., 30(1):255-267 (1988)				
Py	Targacept press release entitled "Targacept and Dr. Falk Pharma Successfully Complete Phase I Studies of First in Class Drug for Ulcerative Colitis," Winston-Salem, NC, October 1, 2002				
PS	Thompson, et al., "Functional bowel disorders and functional abdominal pain," Gut. 45 (Suppl. II): 1143-1147.				
PS	Young, et al. "Mecamylamine: new therapeutic uses and toxicity/risk profile," Clinical Therapeutics 23(4):532-565 (2001).				
175	Zevin, et al, "Nicotine-mecamylamine interactions," Clin. Pharmacol. Ther., 68(1):58-66 (2000).				
Examiner					

*Examiner: Initial if reference considered, whether or not citation is in conformance with MPEP 609; draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO 1449

Patent and Trademark Office - U.S. Department of Commerce

403757_1.DOC

	INF	ORMATION DIS	SCLOSURE CI	IATION		
Atty. Docket No.						
Applicant	John Devane	AUG 1 9 2004 25				
Filing Date	March 12, 2004	AND 1 9 2004 25	Group: 16	14		
		U.S. DATEN	T DOCUMENTS			
		U.S. FAILIN	1	T Class	Sub T	Filing Date
Examiner Initial*	Document Number	Issue Date	Name	Class	Sub Class	If Appropriate
•						
•		EODEIGN DATE	ENT DOCUMENTS			
	Document	Publication	Country	Class	Sub	Translation
	Number	Date	Country	Class	Class	Yes or No
75	WO 00/33812	6/15/2000	PCT			
PS	WO 00/35280	6/22/2000 .	PCT			
741	WO 00/35279	6/22/2000	PCT			
	OTHER ROOMER	TO (Including Au	Abor Tido Dodo I			
	OTHER DOCUMEN					
1/5	Mangel, "Potentiation Journal Of Pharma			stokinin and	otner Pep	itides, <i>European</i>
Braida, et al., "Excitatory and Inhibitory Effects of Second-Generation Cholinesterase Inhibitors on Rat Gastrointestinal Transit," <i>Pharmacological Research</i> , Vol. 41, No. 6, (2000) pgs. 671-677						
		- \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \ \	V		,	•
Examiner	Phulm	>PW/AC	Date Considered	3/28	\$ 106	
th	nitial if reference considering in the constant of the constan	conformance and r				

Patent and Trademark Office - U.S. Department of Commerce

Form PTO 1449